TL;DR
Get everyday helpers delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
A study of 575 GLP-1 receptor agonist users found higher reported rates of nail lifting and discoloration than among 1,329 people with obesity and/or type 2 diabetes who had never used the drugs. But the association disappeared in an analysis limited to nail changes that began after treatment, so the findings do not establish that GLP-1 drugs cause nail disorders.
A study presented at a European dermatology meeting found that people taking GLP-1 receptor agonists reported more nail disorders, including nails separating from the nail bed, than a comparison group that had never used the drugs. However, the researchers found no difference in new-onset nail lifting or discoloration between the groups, and the results do not show that the medications caused the problems.
The prospective study included 575 GLP-1 users and 1,329 people with obesity and/or type 2 diabetes who had never taken a GLP-1 drug. Participants were recruited in France, the United States, Brazil and Mexico. The findings were presented by Bianca Maria Piraccini of the University of Bologna at a European Academy of Dermatology and Venereology meeting in Vienna.
In the reported results, 39.3% of GLP-1 users had onycholysis, or separation of a nail from its nail bed, compared with 8.7% of non-users. Nail discoloration, known as dyschromia, was reported by 45.6% of users and 17.0% of non-users. Fragile nails and ridges or grooves were also more common among users. Overall, 66.3% of users and 52.8% of non-users reported at least one nail disorder, a statistically significant difference.
The comparisons changed when researchers examined timing and other factors. An analysis adjusting for characteristics including age, sex, country and comorbidities continued to find higher odds of onycholysis and discoloration among users. But when investigators counted only nail changes that started after treatment began, they found no difference in onycholysis or dyschromia. The study relied on an online survey, and the groups differed in age: controls averaged 56.7 years, compared with 45.3 years among GLP-1 users.
What the Nail Findings Could Mean
The results may prompt clinicians and patients to pay attention to nail symptoms during GLP-1 treatment, but they do not establish a medication side effect. The gap in reported nail problems could reflect differences between the groups, conditions that existed before treatment, or other factors; the new-onset analysis did not show the same association.
That distinction matters because GLP-1 medicines are used for conditions including type 2 diabetes and obesity. An outside expert, Joe Tung of the University of Pittsburgh Medical Center, told MedPage Today that the findings alone would not justify stopping a medication that is appropriate and working for a patient. He encouraged people who notice nail changes to seek a dermatology assessment, since common causes can be treatable.
nail health supplements for brittle nails
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How Researchers Interpreted the Association
Researchers said that nearly half of the GLP-1 users reported a history of nail problems before starting treatment. Sensitivity analyses that accounted for this history still showed differences in some comparisons, but the analysis of new-onset lesions found no difference. The investigators said the true association, if any, may lie between those results.
Piraccini said weight loss is commonly associated with changes to the nail surface, such as roughness, but argued that nail detachment is not typically a sign of low calorie intake or protein deficiency. She said a direct drug effect was possible and warranted further study. Tung offered a different possible explanation: rapid weight loss and reduced protein or micronutrient intake could affect nails, as they can affect hair. Neither explanation was established by this study.
“Our findings show a clear association, but they also underline an important point: Not everything that happens during GLP-1 treatment is necessarily caused by the treatment itself.”
— Charles Taieb, co-investigator, in an EADV press release
Cause and Timing Remain Unsettled
The study shows a difference in reported nail disorders between groups, not proof that GLP-1 drugs cause nail changes. The absence of a difference in new-onset onycholysis and dyschromia complicates the overall association, particularly because many users said their nail problems predated treatment. Participants reported their symptoms through an online survey rather than having nail disorders confirmed by dermatologists.
The supplied report does not provide enough detail to resolve how much the findings were affected by each group’s differing characteristics or by unmeasured factors. Researchers said the association may fall between the adjusted comparisons and the new-onset analysis. Whether the drugs themselves contribute to nail disorders remains uncertain.
Further Study and Clinical Follow-Up
Piraccini said the findings would prompt further studies. The next research would need to clarify when nail changes begin and examine them in a way that can better distinguish medication effects from pre-existing conditions, weight loss, nutrition and other causes. No follow-up study or timetable was specified in the report.
For now, Piraccini advised clinicians to ask whether nail changes were present before treatment and to examine affected nails. Tung recommended that people who notice changes consult a dermatologist; he said the study does not, on its own, warrant stopping an otherwise beneficial GLP-1 medication.
Key Questions
What nail problems were reported among GLP-1 users?
The study reported more onycholysis, or nail separation, and discoloration among GLP-1 users than among non-users. Fragility and ridges or grooves were also more common in the user group.
Does the study prove GLP-1 drugs cause nails to detach?
No. It found an association in overall reports, but the analysis of nail lifting that began after treatment started showed no difference between users and non-users. The study cannot establish that the medicines caused the nail changes.
Should someone stop a GLP-1 medication because of nail changes?
The outside expert quoted in the report said these findings alone would not justify stopping an otherwise beneficial medication prescribed for an appropriate patient. Anyone concerned about a medication or new symptoms should discuss them with a qualified health professional.
What should patients do if they notice nail changes?
The researchers advised clinicians to ask whether the problem began before or during treatment. Tung recommended seeing a dermatologist, since common causes of nail disorders may be treatable.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
